Aurobindo Pharma Ltd. Results

Q2FY25 Quarterly Result Announced for Aurobindo Pharma Ltd.

Pharmaceuticals company Aurobindo Pharma announced Q2FY25 results Revenue from Operations increased by 8.0% YoY to Rs 7,796 crore with growth across the businesses. US formulations (excluding Puerto Rico) revenue increased by 4.3% YoY to Rs 3,530 crore (USD 421 million). Europe formulations revenue increased by 19.0% YoY to Rs 2,105 crore (EUR 229 million). Growth Markets revenue increased by 44.0% YoY to Rs 812 crore (USD 97 million). ARV revenue decreased by 22.8% YoY to Rs 193 crore (USD 23 million). API revenue remained flat YoY at Rs 1,156 crore (USD 138 million). EBITDA before R&D; stood at Rs 1,954 crores with a margin of 25.1%. EBITDA before Forex and Other Income stood at Rs 1,566 crore; EBITDA margin at 20.1%. Research & Development (R&D; including depreciation) spend was Rs 410 crore, 5.3% of revenues. Received final approval for 8 ANDAs including from the USFDA. Net Profit for the period stood at Rs 817 crore, vs. Rs 752 crore in Q2FY24. Basic & Diluted EPS grew by 9.1% YoY to Rs 14.00 per share K. Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma, said: "We are pleased with the continued growth in revenues across our key business areas this quarter, reflecting the resilience of our diversified portfolio. While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong. With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year."

Q1FY25 Quarterly Result Announced for Aurobindo Pharma Ltd.

Pharmaceuticals company Aurobindo Pharma announced Q1FY25 results: Revenue from Operations increased by 10.5% YoY to Rs 7,567 crore with growth across the businesses US formulations (excluding Puerto Rico) revenue increased by 13.3% YoY to Rs 3,555 crore (USD 426 million) Europe formulations revenue increased by 7.9% YoY to Rs 1,982 crore (EUR 221 million) Growth Markets revenue increased by 49.2% YoY to Rs 709 crore (USD 85 million) ARV revenue increased by 13.9% YoY to Rs 229 crore (USD 27 million) API revenue grew by 5.6% YoY to Rs 1,092 crore (USD 131 million) EBITDA before Forex and Other Income stood at Rs 1,620 crore; EBITDA margin at 21.4% Research & Development (R&D;) spend was Rs 339 crore, 4.5% of revenues Received final approval for 10 ANDAs including 1 Specialty & Injectable product from the USFDA Net Profit after Share of Profit/Loss of JV and Minority Interest at Rs 919 crore, vs. Rs 571 crore in Q1FY24 Basic & Diluted EPS grew by 61.4% YoY to Rs 15.69 per share Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments. Our profitability was sustained by improved gross margins and operational efficiencies, while ramping-up our recently commercialized plants. We are confident in our ability to achieve our growth targets for FY25.”

Q4FY24 Quarterly Result Announced for Aurobindo Pharma Ltd.

Pharmaceuticals company Aurobindo Pharma announced Q4FY24 results: Revenue from Operations increased by 17.1% YoY to Rs 7,580 crore with growth across the businesses US formulations (excluding Puerto Rico) revenue increased by 21.6% YoY to Rs 3,588 crore (USD 432 million) Europe formulation revenue increased by 10.4% YoY to Rs 1,832 crore (EUR 203 million) Growth Markets revenue increased by 49.5% YoY to Rs 852 crore (USD 103 million) ARV revenue increased by 31.5% YoY to Rs 238 crore (USD 29 million) API revenue remained flat YoY at Rs 1,019 crore (USD 123 million) EBITDA before Forex and Other income stood at Rs 1,687 crore; EBITDA margin of 22.3% Research & Development (R&D;) spend stood at Rs 392 crore, 5.2% of revenues (vs. Q3 FY24: 5.4%) Received final approval for 17 ANDAs including 4 specialty & injectable products from the USFDA Net Profit after Share of Profit/Loss of JV and minority interest at Rs 909 crore, vs. Rs 506 crore in Q4FY23 Basic & Diluted EPS grew by 79.5% YoY to Rs 15.51 per share Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are extremely delighted to report a strong performance for the quarter and the year, supported by the expansion into the new markets, product launches and stable pricing. Our improved capacity utilization has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year, while stabilizing the operations of the recently commercialized facilities.”

Q3FY24 Quarterly Result Announced for Aurobindo Pharma Ltd.

Pharmaceuticals company Aurobindo Pharma announced Q3FY24 results: Revenue from Operations increased by 14.7% YoY to Rs 7,352 crore with growth seen across multiple businesses. US formulations (excluding Puerto Rico) revenue increased by 28.9% YoY to Rs 3,756 crore (USD 451 million). Europe formulation revenue increased by 1.6% YoY to Rs 1,728 crore (EUR 193 million). Growth Markets revenue increased by 25.6% YoY to Rs 627 crore (USD 75 million). ARV revenue decreased by 28.6% YoY to Rs 179 crore (USD 22 million). API revenue grew by 7.1% YoY to Rs 1,022 crore (USD 123 million). EBITDA before Forex and Other income stood at Rs 1,601 crore; EBITDA margin of 21.8%. Research & Development (R&D;) spend stood at Rs 398 crore, 5.4% of revenues (vs. Q2 FY24: 4.2%). Received final approval for 16 ANDAs including 7 specialty & injectable products from the USFDA. Net Profit after Share of Profit/Loss of JV and minority interest at Rs 936 crore, vs. Rs 491 crore in Q3FY23. Basic & Diluted EPS grew by 91.4% YoY to Rs 16.04 per share. Board has approved interim dividend @ 150% i.e. Rs 1.5 per equity share of Rs 1/- for FY24. Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are very pleased with the considerable progress we have made in our operations, and the cost efficiencies we have achieved, this quarter’s highest ever sales and EBITDA reflect the same. With our continued focus on developing a strong pipeline and driving the commercialization of our key projects, we are confident of our growth trajectory in the months ahead.”